{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T14:36:18Z","timestamp":1648823778592},"reference-count":21,"publisher":"Japanese Association of Virology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Uirusu"],"published-print":{"date-parts":[[2014]]},"DOI":"10.2222\/jsv.64.35","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T22:08:17Z","timestamp":1425938897000},"page":"35-42","source":"Crossref","is-referenced-by-count":0,"title":["Development of new therapies targeting human papillomavirus molecules"],"prefix":"10.2222","volume":"64","author":[{"given":"Kei","family":"KAWANA","sequence":"first","affiliation":[{"name":"Associate Professor Department of Obstetrics and Gynecology, Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1062","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1)zur Hausen, H. Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer, 2: 342-350, 2002","DOI":"10.1038\/nrc798"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2)Bosch FX, et al.: Human papillomavirus and cervical cancer burden and assessment of causality. J Natl Cancer Inst Monogr, 31: 3-13, 2003.","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3)Human papillomavirus, Nature Outlook,488: 30 Aug, 2012","DOI":"10.1038\/488030a"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4)Ressler S, Scheiden R, Dreier K et al., High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma, Clin Cancer Res, 13: 7067-7072, 2007","DOI":"10.1158\/1078-0432.CCR-07-1222"},{"key":"5","unstructured":"5)Kawana K, Yasugi T, Taketani Y. Human papillomavirus vaccines: current issues and future: Review. Indian J Med Res 2009;130:341-347."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6)Kanodia S, Da Silva DM, Kast WM, Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008;122:247-259","DOI":"10.1002\/ijc.23252"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7)Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106:453-460","DOI":"10.1016\/j.ygyno.2007.04.038"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8)Roman LD, Wilczynski S, Muderspach LI, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007;106:558-566","DOI":"10.1016\/j.ygyno.2007.05.038"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9)Kaufmann AM, Nieland JD, Jochmus I, et al., Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3). Int J Cancer 2007;121:2794-2800","DOI":"10.1002\/ijc.23022"},{"key":"10","unstructured":"10)Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16\/18 oncoproteins. Cancer Res 2003;63:6032-6041"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11)Fiander AN, Tristram AJ, Davidson EJ, et al., Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006;16:1075-1081","DOI":"10.1111\/j.1525-1438.2006.00598.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12)Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103:317-326","DOI":"10.1097\/01.AOG.0000110246.93627.17"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13)Brun JL, Dalstein V, Leveque J, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011;204(2):169","DOI":"10.1016\/j.ajog.2010.09.020"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14)Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3. Clin Cancer Res 2009;15(1):361-367","DOI":"10.1158\/1078-0432.CCR-08-1725"},{"key":"15","unstructured":"15)Nakagawa M, Stites DP, Farhat S et al., Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia. J Infect Dis, 175: 927, 1997."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16)Trimble CL, Peng S, Thoburn C, Kos F, Wu TC. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2\/3. Cancer Immunol Immunother 2010;59:799-803.","DOI":"10.1007\/s00262-009-0806-4"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17)Kunisawa J, Kiyono H: A marvel of mucosal T cells and secretory antibodies for the creation of first lines of defense. Cell Mol Life Sci. 2005;62:1308-21.","DOI":"10.1007\/s00018-005-5035-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18)Ericsson A, Svensson M, Arya A, Agace WW: CCL25\/ CCR9 promotes the induction and function of CD103 on intestinal intraepithelial lymphocytes. Eur J Immunol 2004; 34:27202729.","DOI":"10.1002\/eji.200425125"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19)Kojima S, Kawana K, Fujii T, et al., Characterization of intraepithelial lymphocytes (IELs) residing in the cervical mucosa of patients with human papillomavirus (HPV)-infected intraepithelial neoplastic lesions. Am J Reprod Immunol, in-press, 2011","DOI":"10.1111\/j.1600-0897.2011.01041.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20)Adachi K, Kawana K, Yokoyama T, et al., Oral immunization with Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocyte against HPV16 E7. Vaccine, 28: 2810-2817, 2010","DOI":"10.1016\/j.vaccine.2010.02.005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21)Christie RJ, Matsumoto Y, Miyata K, Nomoto T, Fukushima S, Osada K, Halnaut J, Pittella F, Kim HJ, Nishiyama N, Kataoka K. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano. 26;6(6): 5174-89, 2012","DOI":"10.1021\/nn300942b"}],"container-title":["Uirusu"],"original-title":["HPV\u3092\u6a19\u7684\u306b\u3057\u305f\u5b50\u5bae\u9838\u764c\u306b\u5bfe\u3059\u308b\u5275\u85ac\u958b\u767a"],"language":"en","deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T20:21:08Z","timestamp":1566418868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsv\/64\/1\/64_35\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2222\/jsv.64.35","relation":{},"ISSN":["0042-6857","1884-3433"],"issn-type":[{"value":"0042-6857","type":"print"},{"value":"1884-3433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}